Singaporeans are living longer and not having enough babies to replace themselves, with projected 20% of the population aged 65 years and above by 2030. These worrying trends can exert significant pressure on Singapore's economy and society. Health-resource utilisations are increasing as our population ages, with increase in hospitalisations, emergency room visits and consumption of pharmaceutical drugs. Interventions such as vaccinations in older people are well-studied approaches to prevent infections and the related complications. The Advisory Committee on Immunization Practice (ACIP) by the US Centers for Disease Control and Prevention (CDC) recommends routine immunisation against influenza, tetanus, pneumococcal pneumonia as well as herpes zoster infections in all people aged 65 years and above. The administrations of other vaccines (meningococcal, hepatitis A and B, varicella and Haemophilus influenzae type b) are recommended only in older people with certain risk factors. Despite the benefits of vaccination in older people, the data in the West shows that the rate of vaccination in this age group remains lower than targets recommended by the World Health Organisation (WHO). The main barriers to vaccinations exist in the healthcare system, health care providers, patients and caregivers. Interventions are warranted to increase awareness among physicians, to engage the involvement of the pharmacist/nurse to provide standing orders and reduction in cost of vaccination; this potentially improves vaccination uptake to protect our increasing elderly population.
INTRODUCTION
Improved living standards and current advancements in healthcare system have increased life expectancy, leading to a rapidly aging population in developed countries. It is projected globally that the number of older adults (age 60 years old and above) would be more than double, from 841 million people in 2013 to more than 2 billion by 2050 1 . In Singapore, the national data showed that 11.2% of local population are 65 years old and above in 2014 2 , with this figure expected to increase to 20% in 2030 3 .
In comparison to the younger population, older adults are more vulnerable to infectious diseases with a higher rate of morbidity and mortality 4 . As such, the aging population poses a major challenge to the public healthcare system with increased hospitalisations and length of stay. Studies have shown that vaccination is an effective alternative to protect older adults from preventable infections, hence the subsequent serious complications 5, 6 .
AGEING AND IMMUNITY
Increasing age significantly decreases both innate and adaptive immune system's responses to infection, and this phenomenon was termed "immunosenescence". There are several proposed mechanisms involved in this gradual deterioration of the immune system which affect the ability to respond to infections and the development of long-term immune memory, especially by vaccination. The innate immune system provides the first-line barrier to protect human body from micro-organisms. The main components include 1) epithelial barrier; 2) phagocytic cells (neutrophils, Proceedings of Singapore Healthcare  Volume 24  Number 2  2015 macrophages, dendritic cells); 3) natural killer cells; and 4) circulating plasma proteins. The number and the function of these cells and proteins diminished with age, causing a decrease in inflammatory responses of the innate system 7, 8 .
Alternatively, the adaptive immune system consisting of T-cells and B cells plays a major role in recognition and generation of a series of immunity responses to neutralise or eliminate the evading micro-organisms. Maturation of T cells happens in the thymus, which is located behind the sternum, and in front of the heart. One of the hallmarks of immunosenescence is the reduction in thymus gland size, with gradual replacement of its functional cortex and medulla by fat tissue 7, 9 . As a result, production of mature naive T-cells and their number in the peripheral blood is significantly reduced. Similar to T-cell systems, the number of naive B-cells also decreases in older adults 7, 9 . On the other hand, the number of memory T-cells and B-cells appears to be well preserved with aging 10 . These increased effector T-cells and B-cells number together with their age-related alterations in cytokines and antibodies production cause restriction in the diversity of the immune cell repertoire 6 . As a consequence, the effectiveness and diversity of the adaptive immune response are impaired, which lead to increased susceptibility to infectious diseases as well as decreased immune responses to vaccination in older adults 7, 10 . This phenomenon has been demonstrated in a metaanalysis by Goodwin et al., which showed that seroprotection against influenza virus strains was only 29%-46% in persons aged 75 years, compared with 41%-58% in persons 60-74 years of age 11 .
These changes in the immune system potentially affect successful vaccination in the older population. Therefore, optimisation of immunisation schedules and modes of administration, using new adjuvants and vaccines that specifically address the issues of immunosenescence phenomenon will help to improve protection in this vulnerable population.
VACCINE RECOMMENDATIONS FOR OLDER ADULTS
Since the establishment of the Advisory Committee on Immunization Practice (ACIP) by the US Centers for Disease Control and Prevention (CDC) in 1964, ACIP makes recommendations for adult vaccination program every two years 12 . In the last 15 years, a number of new vaccines have been introduced, including varicella, hepatitis A, pneumococcal, and human papillomavirus vaccines. The latest recommendations on adult vaccinations by the ACIP were published in October 2013 13, 14 . The ACIP recommends routine immunisation against influenza, tetanus, pneumococcal pneumonia as well as herpes zoster (HZ) infection in all adults above 65 years of age. The administrations of other vaccines (meningococcal, hepatitis A and B, varicella and Haemophilus influenzae type b) are recommended only in older adults with high risk factors (Table 1) . Currently, there is no specific vaccination guideline for adults in Singapore.
Influenza
Influenza is a disease caused by highly contagious influenza viruses: type A, type B or type C. Among these, influenza A viruses are the most pathogenic and accounted for more severe illnesses and complications. The Ministry of Health (MOH) in Singapore has a national surveillance program for influenza which monitors the attendance of upper respiratory tract infections (URTI) at government clinics. The months from April to July and November to January are the traditional "influenza seasons" with a distinct peak in reported cases. More than 5,000 cases of acute respiratory infection are reported in polyclinics, hospitals and tertiary care centres across Singapore each year 15 . Although influenza affects people of all ages, older adults (age 65 and above) are at the highest risks of influenzarelated hospitalisations and deaths 16, 17 .
Influenza vaccination has been shown to be clinically effective in reducing the rate of hospitalisations as well as influenza-related mortality in older population [18] [19] [20] . The ACIP recommends annual influenza vaccination starting from age 6 months and above. Older adults should receive inactivated formulation (not the live, intranasal influenza vaccine), either intramuscularly or subcutaneously (depending on the brands). The side effects are rare, mostly limited to local reactions at the injection sites which typically last for less than 48 hours.
Pneumococcal Pneumonia
Pneumococcal disease (PD), caused by the bacterium Streptococcus pneumoniae, is a leading cause of morbidity in children and adults worldwide 21 23 .
In an analysis of 4,275 patient records with PD from 1995-2004 in Singapore, the mean annual hospitalisation rate from PD was 10.9 per 100,000 population but considerably higher among the older adults (>75 years; 95/100,000). The overall mortality rate was 3.2%; with meningitis mortality and pneumococcal pneumonia mortality rates were 23.3% and 2.9% respectively 24 .
There are currently two types of pneumococcal vaccines available: the pneumococcal polysaccharide vaccine (PPV) and the pneumococcal conjugate vaccines (PCV). A Cochrane review in 2013, which included both RCT and non-RCT trials, supported the use of PPV for IPD in the elderly 25 . However, the meta-analysis did not provide the evidence to support the use of PPV to prevent all cause pneumonia or mortality. Vaccine efficacy was also poorer in adults with chronic illness. A second study by Jackson et al. concluded that although vaccination with PPV seems to be effective against pneumococcal bacteraemia, there was no association between PPV vaccination and community acquired pneumonia of any cause (including non-invasive pneumococcal pneumonia) among older adults 26 . The study also found an unexplained increased risk of hospitalisation for community acquired pneumonia for vaccinated patients. Recently, CAPiTA (Community Acquired Pneumonia Immunization Trial in Adults), a randomised placebo controlled double-blind trial was conducted in the Netherlands from 2008 to 2013 among approximately 85,000 patients age 65 and older to study the efficacy of PCV13 (funded by Pfizer). It is the first trial to show efficacy of a vaccine against not only vaccinetype IPD (75% efficacy, CI of 41.4-90.8%) but also vaccine-type non-bacteraemic pneumococcal disease (45% efficacy, CI of 14.2-65.3%) in the elderly population 27 .
After the release of the CAPiTA result, the ACIP endorsed the routine use of both PCV13 and PPSV23 in adults aged ≥65 years since August 2014 28 . The two vaccines should not be co-administered, and the minimum acceptable interval between PCV13 and PPSV23 is 8 weeks. The ACIP recommends that PCV13 should be given first, followed by PPSV23 after 6-12 months. However, if PPSV23 has already been given, PCV13 should only be given after 1 year. While local adverse reactions including pain, redness and swelling at the injection site are common, systemic reactions are rare.
Herpes Zoster
Herpes zoster is caused by the reactivation of the varicella-zoster virus (VZV). The clinical manifestations include development of painful vesicular rash along one or two dermatomes. The infection is commonly complicated by postherpetic neuralgia (PNH), which is presented as persistent neuropathic pain along the affected dermatome. The incidence of HZ rises with age due to aging related weakening of T cell-mediated immunity, and the reported rate is around 10 cases per 1,000 U.S. populations annually among adults age 60 years and above 29 .
The Shingles Prevention Study (SPS) has illustrated that a highly potent live attenuated VZV vaccine could potentially reduce the overall incidence of HZ infection as well as PNH in adults age 60 years and above 30 . However, a follow-up study, Short Term Persistence Substudy (STPS) for Shingles Prevention Study indicated possible waning of protection against HZ overtime 31 In conclusion, the ACIP recommends the use of vaccine against VZV (causing HZ) in all older adults ≥60 years old, with or without any previous episode of HZ. It can be given subcutaneously and it is contraindicated in immunocompromised persons. 35 . Similar findings were also reported in another study in England 36 . However, there is a dearth of such data in Singapore.
Studies were conducted to investigate the barriers of low vaccination rate in adults [37] [38] [39] [40] . The three main barriers identified to vaccinations in older adults can be classified under barriers in system, health care provider and patient or caregiver ( Table 2) . Several factors were recognised to improve the uptake of vaccinations in older adults, which includes physician recommendation, previous history of the illness, self-reported bad health conditions, perception on the efficacy of vaccination and family influences [41] [42] [43] . A number of strategies have been shown to improve vaccination rate in older adults, which consists of:
(1) Implementation of a reminder/recall system for patients and health care providers;
(2) Reduction in vaccination costs;
(3) Expansion of access to vaccinations in medical or public health settings; and (4) Implementation of standing orders (the use of a nurse-led or pharmacist-led immunisation program) 44-47 .
CONCLUSION
Vaccination is potentially the most cost-effective public healthcare measure, providing significant protection against infectious diseases and their complications for older adults with agerelated decline in their immune system. Further investigations are required to show reproducibility in efficacy of vaccines in older patients, as the viral load and local immunity may not be the same as that in published studies. There are also opportunities for more studies on vaccination efficacy in a subgroup of elderly that are above 80 years of age with frailty, multiple co-morbidities and that are not community-ambulant. Further research on the mechanisms of immunosenescence, the development of new adjuvants and other immunotherapy, coupled with initiatives to improve immunisation uptake in the elderly, will definitely help to achieve better protection for the increasing elderly population in Singapore. 
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